TELA Stock: Price, Forecast, Financials & AI Analysis

Loading...

Loading chart...

High

0.835

Open

0.820

VWAP

0.79

Vol

65.82K

Mkt Cap

34.73M

Low

0.761

Amount

52.13K

EV/EBITDA(TTM)

--

Total Shares

44.53M

EV

45.92M

EV/OCF(TTM)

--

P/S(TTM)

0.45

TELA Bio, Inc. is a commercial-stage medical technology company. The Company is focused on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient’s own anatomy. Its first portfolio of products, the OviTex Reinforced Tissue Matrix (OviTex), addresses unmet needs in hernia repair and abdominal wall reconstruction. Its OviTex portfolio consists of multiple product configurations intended to address various surgical procedures within hernia repair and abdominal wall reconstruction, including ventral, inguinal, and hiatal hernia repair. The Company's OviTex products include OviTex 1S, OviTex 2S, OviTex LPR, and OviTex IHR. Its second portfolio of products, the OviTex PRS Reinforced Tissue Matrix (OviTex PRS), addresses unmet needs in plastic and reconstructive surgery. OviTex PRS is indicated for use in implantation to reinforce soft tissue where weakness exists in patients requiring soft-tissue repair.

Show More

Events Timeline

(ET)

2025-12-12

07:20:00

Tela Bio Files to Sell 2M Shares of Common Stock

2025-12-01 (ET)

2025-12-01

08:50:00

Lake Street Lowers Tela Bio Price Target to $3 Amid Q3 Results Shortfall

2025-11-13 (ET)

2025-11-13

16:12:31

Tela Bio projects at least a 16% increase in FY25 revenue.

2025-11-13

16:11:53

Tela Bio announces Q3 earnings per share of 19 cents, below consensus estimate of 20 cents.

2025-08-11 (ET)

2025-08-11

16:28:14

Tela Bio backs FY25 revenue view $85M-$88M, consensus $86.05M

2025-08-11

16:27:34

Tela Bio reports Q2 EPS (22c), consensus (19c)

2025-06-03 (ET)

2025-06-03

16:47:07

Tela Bio announces European launch of OviTex Inguinal Reinforced Tissue Matrix

News

Benzinga

2025-12-23Benzinga

BDX Faces Monopoly Allegations in U.S. Hernia Mesh Market, Impacting Patient Choices

SeekingAlpha

2025-12-22SeekingAlpha

Becton, Dickinson Faces Allegations of Stifling Competition in Hernia Mesh Industry

Globenewswire

2025-12-12Globenewswire

TELA Bio Grants 3,600 Restricted Stock Units to New Employees

Newsfilter

2025-12-12Newsfilter

TELA Bio Grants 3,600 Restricted Stock Units to New Employees

Benzinga

2025-11-18Benzinga

Alphabet Set to Surge Over 12%? Check Out 10 Leading Analyst Predictions for Tuesday

Benzinga

2025-11-18Benzinga

Canaccord Genuity Keeps Buy Rating on TELA Bio, Reduces Price Target to $4

4 Analyst Rating

Wall Street analysts forecast TELA stock price to rise

3 Buy

1 Hold

0 Sell

Strong Buy

Current: 0.000

Low

1.25

Averages

3.31

High

5.00

Current: 0.000

Low

1.25

Averages

3.31

High

5.00

Canaccord

Buy

downgrade

$7 -> $4

AI Analysis

2025-11-18

Reason

Canaccord

Price Target

$7 -> $4

AI Analysis

2025-11-18

downgrade

Buy

Reason

Canaccord lowered the firm's price target on Tela Bio (TELA) to $4 from $7 and keeps a Buy rating on the shares. The firm said they posted a challenged Q3 as it missed top-line expectations and lowered full-year guidance, though it reiterated confidence in its commercial strategy and sales force structure as recent hires Jeffrey Blizzard and Jim Hagen from Abiomed (ABMD) become increasingly important pieces to the Tela Bio story.

Citizens JMP

Outperform

to

NULL

downgrade

$7 -> $5

2025-11-14

Reason

Citizens JMP

Price Target

$7 -> $5

2025-11-14

downgrade

Outperform

to

NULL

Reason

Citizens JMP lowered the firm's price target on Tela Bio to $5 from $7 and keeps an Outperform rating on the shares. Quarterly sales were shy of the Street by about 5%, reflecting several meaningful highlights, such as strong international sales and the addition of new customers, the analyst tells investors in a research note. The cons outweighed the pros, and management lowered its top-line guidance by 9% year over year, the firm adds.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for TELA

Unlock Now

Valuation Metrics

The current forward P/E ratio for TELA Bio Inc (TELA.O) is -1.82, compared to its 5-year average forward P/E of -4.23. For a more detailed relative valuation and DCF analysis to assess TELA Bio Inc's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

dotted line Image

N/A

5Y Average PE

-4.23

Current PE

-1.82

Overvalued PE

-2.62

Undervalued PE

-5.84

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

dotted line Image

N/A

5Y Average EV/EBITDA

-5.31

Current EV/EBITDA

-3.07

Overvalued EV/EBITDA

-3.14

Undervalued EV/EBITDA

-7.47

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

dotted line Image

5Y Average PS

2.70

Current PS

0.57

Overvalued PS

4.40

Undervalued PS

1.00

Financials

AI Analysis

Annual

Quarterly

Related Community Screener

list of strong buy stocks under $3.00

Intellectia · 94 candidates

Price: <= $3.00Analyst Consensus: Strong Buy

Ticker

Name

Market Cap$

Akari Therapeutics PLC

9.32M

Plus Therapeutics Inc

52.05M

Reviva Pharmaceuticals Holdings Inc

38.21M

Intensity Therapeutics Inc

23.85M

Mereo BioPharma Group PLC

84.34M

Atossa Therapeutics Inc

77.93M

Whales Holding TELA

Pentwater Capital Management LP

Trading Trends

People Also Watch

Frequently Asked Questions

What is TELA Bio Inc (TELA) stock price today?

The current price of TELA is 0.78 USD — it has decreased -7.36

What is TELA Bio Inc (TELA)'s business?

TELA Bio, Inc. is a commercial-stage medical technology company. The Company is focused on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient’s own anatomy. Its first portfolio of products, the OviTex Reinforced Tissue Matrix (OviTex), addresses unmet needs in hernia repair and abdominal wall reconstruction. Its OviTex portfolio consists of multiple product configurations intended to address various surgical procedures within hernia repair and abdominal wall reconstruction, including ventral, inguinal, and hiatal hernia repair. The Company's OviTex products include OviTex 1S, OviTex 2S, OviTex LPR, and OviTex IHR. Its second portfolio of products, the OviTex PRS Reinforced Tissue Matrix (OviTex PRS), addresses unmet needs in plastic and reconstructive surgery. OviTex PRS is indicated for use in implantation to reinforce soft tissue where weakness exists in patients requiring soft-tissue repair.

What is the price predicton of TELA Stock?

Wall Street analysts forecast TELA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for TELA is3.31 USD with a low forecast of 1.25 USD and a high forecast of 5.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is TELA Bio Inc (TELA)'s revenue for the last quarter?

TELA Bio Inc revenue for the last quarter amounts to 20.69M USD, increased 9.14

What is TELA Bio Inc (TELA)'s earnings per share (EPS) for the last quarter?

TELA Bio Inc. EPS for the last quarter amounts to -0.19 USD, decreased -54.76

How many employees does TELA Bio Inc (TELA). have?

TELA Bio Inc (TELA) has 209 emplpoyees as of March 12 2026.

What is TELA Bio Inc (TELA) market cap?

Today TELA has the market capitalization of 34.73M USD.